Teladoc Q3 revenue up 81% YoY to $522M; updates FY2021 revenue outlook to $2.015-$2.025B

Teladoc Health, Inc.

2022-Q3 EPS reported -$2.68 revenue$1,478,472,000

Net loss of $84.3M ($0.53 per share) vs $35.9M loss ($0.43) in Q3 2020.
Adjusted EBITDA rose to $67.4M from $39.5M; total visits 3.9M (+37% YoY).
U.S. paid membership grew to 52.5M (+2% YoY); chronic care enrollment 0.725M.
New agreements with CVS Health and Centene for Primary360 primary care model.
2021 full-year revenue outlook raised to $2.015B-$2.025B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.